Scientists at The Scripps Research Institute (TSRI) have achieved a major milestone toward designing a safe and effective vaccine to both treat heroin addiction and block lethal overdose of the drug.
Their research, published today in the journal Molecular Pharmaceutics, shows how a new anti-heroin formulation that is safe in animal models remains stable at room temperature for at least 30 days. As a result, the vaccine is close to being ready for human testing.
“The heroin vaccine is one step closer to clinical evaluation,” says Candy S. Hwang, PhD, first author of the study and a research associate at TSRI.
According to the National Institute on Drug Abuse, 15,446 Americans died from heroin overdose between 2000 and 2016, and the mortality rates are increasing. Heroin abuse has been further fueled by a rise in prescription opioid abuse—studies show that opioid pain reliever users are 40 times more likely to abuse heroin.
The first formulation of the heroin vaccine was developed in 2013 by a team led by Kim D. Janda, PhD, the Ely R. Callaway Jr. Professor of Chemistry and member of the Skaggs Institute for Chemical Biology at TSRI. It has been shown to be effective—and safe—in both mouse and non-human primate models.
The vaccine works by training the immune system antibodies to recognize and bind to heroin molecules, blocking the drug from reaching the brain to cause a “high.” Researchers believe that blocking the high of heroin will help eliminate the motivation for many recovering addicts to relapse into drug use.
The heroin molecule does not naturally prompt an antibody response, so researchers attach it to a carrier protein that alerts the immune system to start making antibodies. Scientists also add an ingredient called an adjuvant to the vaccine, which boosts the immune response and makes the vaccine more effective.
Hwang says, “Our goal was to prepare a vaccine that could be advanced to clinical trials. As such, we were looking for the best combination of ‘hapten’ (the heroin molecule), carrier protein and adjuvant to keep the vaccine both stable for transport and storage but still efficacious.”
For the new study, the researchers investigated how 20 different carrier protein/adjuvant combinations worked, including shelf stability based on temperature and storage time and whether the formulation was a liquid or powder.
Their experiments in rodent models showed that the best vaccine formulation contained a carrier protein called tetanus toxoid (TT) and adjuvants called alum and CpG ODN. The discovery that alum worked best as an adjuvant was especially significant since alum is one of the few adjuvants used in vaccines already approved by the U.S. Food and Drug Administration. The researchers also found that there was no difference in how well it worked between the liquid and powder versions of this formulation.
Hwang notes that the best vaccine formulation showed protection against lethal doses of heroin. This is particularly important as many heroin addicts have succumb to overdose and death during their attempts to quit the drug.
With this new study, the researchers have shown that the vaccine is safe and effective in animal models, stable under clinical conditions and reliant on an already-approved adjuvant. The next step is to find a producer to make the vaccine on a large scale.
“We believe that a heroin vaccine would be tremendously beneficial for people who have a heroin substance use disorder but have found difficulty in trying to quit,” says Hwang.
Learn more: Heroin vaccine blocks lethal overdose
The Latest on: Heroin vaccine
- Hurdle But No Hurl: Vaxart Starts Phase Ib Norovirus Vaccine Trials on April 17, 2019 at 2:01 pm
Dr. Josh Bloom, the Director of Chemical and Pharmaceutical Science, comes from the world of drug discovery, where he did research for more than 20 years. The field of drug discovery involves ... […]
- Manufacturer to Produce Cell-Based Flu Vaccine for Next Season on April 17, 2019 at 9:58 am
These copies allow drug manufacturers to mass produce flu vaccines equivalent to the strains determined by the WHO, according to the statement. A recent study compared egg-based CVVs to cell-based ... […]
- Republicans reject Democrat-led attempts at tightening state vaccine laws on April 17, 2019 at 8:00 am
... drug costs” by expediting generic and biosimilar drug approvals. He added that it would be good for patients if FDA helped speed development for gene and cell therapies. …Boosting vaccine ... […]
- Robust Responses Found in 20-Serotype Pneumococcal Vaccine Trial on April 17, 2019 at 6:20 am
they saw geometric mean fold-rises from baseline ranging from 6.1 to 68.6 for the serotypes in common with pneumococcal 13-valent conjugate vaccine, and 9 to 112.2 for the 7 additional serotypes not ... […]
- The global vaccines market is expected to reach US$ 64,538.4 Mn in 2027 from US$ 36,998.8 in 2018 on April 16, 2019 at 5:24 pm
Some of the major primary and secondary sources for vaccines included in the report are World Health Organization (WHO), European Medical Agency (EMA), Advisory Committee on Immunization Practices ... […]
- New Clinical Trial Will Test WT1 Immunotherapy Drug with Nivolumab for Recurrent Mesothelioma on April 16, 2019 at 9:09 am
One of the latest clinical trials expected to begin soon at Memorial Sloan Kettering Cancer Center is aiming to test the latest immunotherapy drug, a vaccine called galinpepimut-S (sometimes referred ... […]
- Enesi and Oxford University look to create first effective plague vaccine on April 16, 2019 at 3:32 am
Enesi has already established multiple collaborations to develop ImplaVax-enabled vaccines for a range of infectious diseases and allergies. Last year, the US Food and Drug Administration announced ... […]
- Dating after 40? The millions who are should get the HPV vaccine on April 16, 2019 at 1:55 am
to a October 2018 decision by the Food & Drug Administration, women and men aged 27 through 45 finally have the opportunity to obtain Gardasil 9 (the latest version of the vaccine) protect ourselves ... […]
- Novavax faces delisting threat following failed drug trial on April 15, 2019 at 12:43 pm
The threat from Nasdaq comes on the heels of a failed drug trial — the company’s second such failure ... before the company announced that failed phase 3 trial, in which its vaccine candidate for ... […]
- Seqirus Announces Further Advances in Cell-Based Influenza Vaccine Technology on April 15, 2019 at 5:30 am
today announced it will file an Annual Strain Update with the U.S. Food and Drug Administration (FDA) in the coming weeks, including the decision to manufacture its cell-based influenza vaccine ... […]
via Google News and Bing News